<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30588">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708511</url>
  </required_header>
  <id_info>
    <org_study_id>GYNOVA0033</org_study_id>
    <secondary_id>NCI-2015-00767</secondary_id>
    <secondary_id>32991</secondary_id>
    <secondary_id>GYNOVA0033</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02708511</nct_id>
  </id_info>
  <brief_title>Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer</brief_title>
  <official_title>64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjiv Sam Gambhir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography
      (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer
      antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer
      cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu
      64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the dosimetry of 64Cu-DOTA B-Fab (copper Cu 64-DOTA-B-Fab).

      SECONDARY OBJECTIVES:

      I. To evaluate the safety of 64Cu-DOTA B-Fab single administration. II. To evaluate the
      ability of 64Cu-DOTA B-Fab to detect CA6-positive ovarian and breast cancer lesions.

      III. To compare PET results with the immunohistochemistry (IHC) analysis of the excised
      tumor samples.

      OUTLINE:

      Patients receive copper Cu 64-DOTA-B-Fab intravenously (IV) followed by PET/CT immediately
      after injection, at 60 minutes, 120 minutes, and at 24 hours.

      After completion of study, patients are followed up for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of copper Cu 64 DOTA-B-Fab</measure>
    <time_frame>Up to day 8</time_frame>
    <description>Determined from serial imaging correlated with blood and urine samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry of copper Cu 64 DOTA-B-Fab</measure>
    <time_frame>Up to day 8</time_frame>
    <description>Determined from serial imaging correlated with blood and urine samples.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT immediately after injection, at 60 minutes, 120 minutes, and at 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper Cu 64-DOTA B-Fab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (Cu 64 DOTA-B-Fab)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is â‰¥ 18 years old at the time of the drug administration

          -  Patient provides written informed consent

          -  Participant diagnosed with ovarian or breast cancer and scheduled to undergo surgical
             excision of the cancerous lesion(s)

          -  Able to remain still for duration of each imaging procedure

        Exclusion Criteria:

          -  Participant is less than 18 year-old

          -  Participant is pregnant or breast-feeding

          -  Patients with contraindications for PET/CT or who cannot complete a PET/CT scan.
             Patients not able to comply with the study procedures

          -  Patients with serious uncontrolled concurrent medical illness that would limit
             compliance with study requirements

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; 2

          -  Patients participating in other research protocols will be excluded from this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Gambhir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krithika Rupnarayan</last_name>
    <phone>650-736-0959</phone>
    <email>krupnara@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krithika Rupnarayan</last_name>
      <phone>650-736-0959</phone>
      <email>krupnara@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Gambhir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 12, 2017</lastchanged_date>
  <firstreceived_date>November 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sanjiv Sam Gambhir</investigator_full_name>
    <investigator_title>Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
